Generic ATORVASTATIN CALCIUM; EZETIMIBE INN equivalents, drug patent expiry and freedom to operate

Sponsor	Phase
Linyi People's Hospital	PHASE2
Chinese University of Hong Kong	PHASE2
Chong Kun Dang Pharmaceutical	Phase 1

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pharmobedient	LYPQOZET	atorvastatin calcium; ezetimibe	TABLET;ORAL	206084-004	Apr 26, 2017		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Organon	LIPTRUZET	atorvastatin calcium; ezetimibe	TABLET;ORAL	200153-002	May 3, 2013		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Organon	LIPTRUZET	atorvastatin calcium; ezetimibe	TABLET;ORAL	200153-004	May 3, 2013		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Organon	LIPTRUZET	atorvastatin calcium; ezetimibe	TABLET;ORAL	200153-003	May 3, 2013		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Pharmobedient	LYPQOZET	atorvastatin calcium; ezetimibe	TABLET;ORAL	206084-002	Apr 26, 2017		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: September 9, 2026

Atorvastatin calcium is a mature, highly commoditized statin with global generic competition and limited branded revenue. Ezetimibe retains greater commercial value because it is used as an add-on or alternative to statin therapy, but its core U.S. exclusivity has also expired. The atorvastatin-ezetimibe combination remains commercially relevant through generic fixed-dose products and European brands such as Atozet, although price pressure is increasing.

What are atorvastatin calcium and ezetimibe used for?

Atorvastatin calcium is an HMG-CoA reductase inhibitor used to reduce low-density lipoprotein cholesterol, total cholesterol, triglycerides, and cardiovascular risk. Ezetimibe inhibits intestinal cholesterol absorption through the NPC1L1 pathway and is used alone or with a statin.

The combination addresses patients who do not reach LDL-C targets with statin therapy alone or who require additional LDL reduction without substantially increasing statin exposure.

Product	Active ingredient	Drug class	Primary use	Current market status
Lipitor and generic atorvastatin	Atorvastatin calcium	Statin	Hypercholesterolemia and cardiovascular risk reduction	Fully genericized
Zetia and generic ezetimibe	Ezetimibe	Cholesterol absorption inhibitor	Hypercholesterolemia and cardiovascular risk reduction	Generic competition
Vytorin	Ezetimibe/simvastatin	Fixed-dose combination	Hypercholesterolemia	Mature, largely generic
Liptruzet	Ezetimibe/atorvastatin	Fixed-dose combination	Hypercholesterolemia	U.S. brand discontinued
Atozet and generic equivalents	Ezetimibe/atorvastatin	Fixed-dose combination	Hypercholesterolemia	Active in several non-U.S. markets

The FDA label for ezetimibe supports use with statins, fenofibrate, or alone in selected patients. The atorvastatin label supports a broad range of doses, generally from 10 mg to 80 mg daily.[1,2]

How large is the atorvastatin and ezetimibe market?

Atorvastatin is one of the largest generic pharmaceutical markets by prescription volume. Its economic value comes from scale rather than exclusivity. Ezetimibe has a smaller prescription base but higher revenue per prescription in branded and combination markets.

Atorvastatin market dynamics

Lipitor, marketed by Pfizer, was the world’s leading pharmaceutical product before patent expiry. Global annual sales exceeded $10 billion at peak and reached approximately $13 billion in 2010.[3] U.S. generic entry began after expiration of the principal atorvastatin patent estate in 2011.

The post-expiry market developed rapidly:

Multiple manufacturers entered the U.S. market.
Wholesale prices fell sharply.
Retail and mail-order channels shifted toward low-cost generic supply.
Pharmacy benefit managers treated atorvastatin as a preferred or lowest-cost statin.
Brand Lipitor became a limited niche product.

Current value is distributed among manufacturers such as Viatris, Teva, Sandoz, Dr. Reddy's Laboratories, Sun Pharma, Zydus, Torrent, and numerous regional suppliers. No single company controls the global atorvastatin market.

Ezetimibe market dynamics

Ezetimibe initially had a more concentrated commercial market. Merck marketed Zetia and Vytorin, while Schering-Plough and Merck controlled the original U.S. commercialization structure before the companies merged.

Zetia generated approximately $2.4 billion in global sales in 2016 before broader generic erosion. Organon inherited the product portfolio following Merck's 2021 spinoff of its women's health, established brands, and biosimilars businesses. Organon's cardiovascular portfolio, including Zetia and related products, continues to produce material revenue, although generic competition limits pricing power.[4,5]

Ezetimibe remains commercially durable because:

It is widely used as an add-on to high-intensity statins.
It has a low-cost generic price point.
It is incorporated into treatment pathways for patients who do not reach LDL targets on statins.
It is used when higher statin doses are poorly tolerated.
It is included in fixed-dose combinations with atorvastatin, rosuvastatin, and simvastatin.

What patents protect atorvastatin calcium and ezetimibe?

The core composition-of-matter patents for both molecules have expired. Commercial protection now depends on secondary patents, regulatory exclusivities in limited markets, trademarks, manufacturing scale, and distribution contracts.

Drug	Representative originator	Core patent position	U.S. generic status	Current protection
Atorvastatin calcium	Pfizer	U.S. Patent No. 4,681,893 and related atorvastatin patents	Generic entry began in 2011	No meaningful core-molecule exclusivity
Ezetimibe	Merck/Schering-Plough	U.S. Patent No. 5,767,115 and related patents	Generic entry followed expiry of core protection and litigation settlements	Limited secondary protection; no broad U.S. market exclusivity
Ezetimibe/atorvastatin	Merck and commercial partners	Combination and formulation patents in multiple jurisdictions	Generic and regional products available	Product-specific formulation and jurisdictional claims

Atorvastatin's principal U.S. patent protection expired in 2011, with pediatric exclusivity extending the effective period for some products. Ezetimibe's key U.S. exclusivity period ended later, with generic competition becoming commercially significant from 2017 onward.[6,7]

Patent protection varies by country. European, Canadian, Japanese, and emerging-market expiration dates can differ because of patent filing dates, supplementary protection certificates, pediatric extensions, national opposition proceedings, and local settlements.

When did atorvastatin and ezetimibe lose exclusivity?

Atorvastatin exclusivity timeline

Date	Event
1987	Lipitor received U.S. FDA approval
1990s-2000s	Pfizer expanded global commercialization
2011	Core U.S. patent protection expired; generic entry began
2012 onward	Generic atorvastatin became the dominant U.S. supply source
2015 onward	Brand Lipitor became a small residual market

Generic atorvastatin entered the U.S. market through multiple abbreviated new drug applications. The first-wave entrants captured substantial share because atorvastatin was already a high-volume product with established clinical demand.

Ezetimibe exclusivity timeline

Date	Event
2002	Zetia received U.S. approval
2004	Vytorin, the ezetimibe/simvastatin combination, received U.S. approval
2016	Core U.S. patent term approached expiration
2017-2018	Generic ezetimibe and combination competition expanded
2020 onward	Branded revenue continued but with sustained generic erosion

Ezetimibe retained value after patent expiry because it had strong guideline familiarity, high physician awareness, and a large installed base of statin-treated patients. The product therefore experienced a slower commercial decline than many small-molecule drugs with similar patent histories.

What is the FDA and Orange Book status of these products?

Atorvastatin, ezetimibe, and several combinations are approved small-molecule products listed in FDA databases. Their market access is governed primarily through abbreviated new drug applications rather than biologics licensing applications.

The FDA Orange Book records patents and regulatory exclusivity relevant to listed products. For mature generic products, Orange Book listings are less commercially decisive than they are for newly launched medicines because:

Core composition patents have expired.
Multiple ANDA holders are approved.
Most remaining claims relate to formulations, combinations, or methods of use.
Generic manufacturers can often design around secondary claims.

The FDA classifies atorvastatin and ezetimibe as small-molecule drugs. No biosimilar pathway applies. Competitors file ANDAs, demonstrate pharmaceutical equivalence and bioequivalence, and rely on the reference product's safety and efficacy findings.

Which companies challenged the patents?

Ezetimibe generated more meaningful Paragraph IV activity than atorvastatin because the reference product reached the market later and retained higher branded value at the time of generic challenge.

Generic applicants and potential challengers included major manufacturers such as Teva, Glenmark, Mylan, Dr. Reddy's Laboratories, and other ANDA sponsors. Challenges generally focused on patent validity, enforceability, and non-infringement.

Atorvastatin also produced significant patent litigation before generic launch. Pfizer litigated with multiple generic manufacturers over atorvastatin calcium and related formulations. The main commercial outcome was delayed generic entry followed by rapid erosion once the relevant barriers expired.

Paragraph IV litigation matters less today for the base molecules. The relevant risk has shifted toward:

Fixed-dose combination claims.
Polymorph and crystalline-form claims.
Manufacturing-process claims.
Pediatric and geriatric formulations.
Modified-release or abuse-deterrent delivery claims, where applicable.
Jurisdiction-specific patents outside the United States.

What formulations are protected by atorvastatin and ezetimibe patents?

The principal marketed forms are conventional immediate-release oral tablets. Formulation differentiation is limited, which reduces the scope for premium pricing.

Atorvastatin formulations

Commercial products include:

10 mg, 20 mg, 40 mg, and 80 mg tablets.
Calcium salt formulations.
Film-coated immediate-release tablets.
Fixed-dose combinations with amlodipine, ezetimibe, and other cardiovascular agents.

Secondary intellectual property may cover salt form, particle characteristics, tablet composition, stability, and manufacturing processes. These claims generally do not prevent broad generic substitution when the generic product uses a non-infringing process or formulation.

Ezetimibe formulations

Commercial products include:

10 mg immediate-release tablets.
Ezetimibe/simvastatin tablets.
Ezetimibe/atorvastatin tablets.
Ezetimibe/rosuvastatin combinations.
Ezetimibe with antihypertensive combinations in selected markets.

The most defensible post-expiry opportunities are fixed-dose combinations and region-specific formulations. These products may secure separate approvals and regulatory listings even when the individual ingredients are fully genericized.

How strong is the patent estate for atorvastatin and ezetimibe?

The base-molecule patent estates are weak from a current commercial-exclusivity perspective.

Factor	Atorvastatin	Ezetimibe
Core composition patent strength	Very low after expiry	Very low after expiry
Number of generic suppliers	High	High and increasing
Secondary formulation value	Low to moderate	Moderate
Combination-product value	Moderate	Moderate to high
Manufacturing barriers	Low to moderate	Moderate
Litigation leverage	Low	Low to moderate
Ability to sustain premium pricing	Minimal	Limited

Ezetimibe has the stronger residual commercial position because it remains differentiated pharmacologically from statins and is embedded in combination therapy. Atorvastatin is more exposed to substitution by rosuvastatin, simvastatin, pravastatin, and other generic statins.

Neither drug has a patent estate comparable to a protected specialty medicine or biologic. The main barriers are operational rather than legal: active pharmaceutical ingredient quality, regulatory compliance, supply continuity, and tender access.

How does atorvastatin compare with ezetimibe financially?

Metric	Atorvastatin calcium	Ezetimibe
Peak branded product	Lipitor	Zetia/Vytorin
Peak annual sales	About $13 billion globally	More than $2 billion for Zetia before full generic erosion
Patent expiry impact	Immediate and severe	Significant but more gradual
Current commercial model	High-volume generic	Generic base plus residual branded and combination revenue
Pricing power	Very low	Low to moderate in selected branded markets
Main competitors	Rosuvastatin, simvastatin, pravastatin, generics	Statins, PCSK9 inhibitors, bempedoic acid, inclisiran
Growth driver	Volume and procurement efficiency	Combination use and LDL target intensification
Main risk	Price compression	Generic substitution and therapeutic competition

Atorvastatin's revenue trajectory is volume-led. Manufacturers can remain profitable at low prices because of large prescription volumes, established manufacturing processes, and predictable demand.

Ezetimibe retains better revenue quality in markets where branded prescriptions remain common. Organon's financial exposure is concentrated in mature brands and is vulnerable to continued price and volume erosion. Generic manufacturers can still generate attractive returns if they maintain supply reliability and secure preferred formulary positions.

What competitive drugs affect ezetimibe revenue?

Ezetimibe competes with both low-cost statins and newer LDL-lowering drugs.

Direct and adjacent competitors

Rosuvastatin: high-intensity generic statin and the strongest direct alternative.
Simvastatin and pravastatin: lower-cost generic statins.
Bempedoic acid: oral non-statin option, particularly relevant for statin-intolerant patients.
PCSK9 monoclonal antibodies: alirocumab and evolocumab, used mainly in high-risk patients.
Inclisiran: long-acting PCSK9-directed therapy.
Bile acid sequestrants and fibrates: narrower roles.

Ezetimibe generally occupies the low-cost non-statin step before expensive injectable therapies. That positioning supports prescription volume but limits pricing because payers often require generic ezetimibe before covering PCSK9 therapies.

What generic launch scenarios exist for atorvastatin-ezetimibe?

The combination market has three main launch scenarios.

Scenario 1: Standard generic substitution

Manufacturers launch bioequivalent tablets in commonly used strengths, including 10/10 mg, 10/20 mg, 10/40 mg, and 10/80 mg. Payers substitute these products rapidly, producing price declines similar to other cardiovascular generics.

Scenario 2: Regional fixed-dose expansion

Manufacturers target Europe, Latin America, Asia, and selected Middle Eastern markets where combination products have strong physician acceptance. Local brands and tender contracts may support higher margins than the U.S. market.

Scenario 3: Portfolio bundling

Large generic companies bundle atorvastatin-ezetimibe with rosuvastatin, antihypertensives, antiplatelets, and diabetes products. The value lies in procurement and sales coverage rather than patent exclusivity.

The largest risk to a new entrant is not patent infringement. It is obtaining competitive cost of goods, regulatory approvals across jurisdictions, and reliable supply at a price accepted by national health systems and pharmacy benefit managers.

What litigation and settlement issues affect these products?

The primary historical litigation involved:

Pfizer's enforcement of atorvastatin patents against ANDA applicants.
Merck and Schering-Plough enforcement of ezetimibe and ezetimibe-combination patents.
Paragraph IV challenges involving validity, infringement, and patent-term interpretation.
Settlements that controlled the timing of generic launch in specific jurisdictions.

Current litigation risk is lower for the base products because generic supply is established. New disputes are more likely to involve:

Combination tablet patents.
Brand-versus-generic substitution practices.
Product labeling and method-of-use claims.
Manufacturing processes.
Regulatory exclusivity or data-protection rights outside the United States.

What licensing deals influence the market?

The most important commercial transactions were originator and portfolio transfers rather than new discovery licenses.

Merck and Schering-Plough combined their operations, consolidating Zetia and Vytorin commercialization.
Organon acquired the established-products portfolio when it separated from Merck in 2021.
Generic companies expanded through supply agreements, regional licenses, and contract manufacturing arrangements.

Atorvastatin's commercial rights are broadly dispersed after Lipitor's patent expiry. Ezetimibe remains more concentrated in certain branded markets because Organon continues to commercialize Zetia and related products.

What is the revenue outlook for atorvastatin and ezetimibe?

Atorvastatin revenue should remain stable in aggregate but continue shifting from branded sales to low-margin generic volume. Growth is likely to come from population aging, cardiovascular risk screening, and expanded treatment guidelines rather than pricing.

Ezetimibe should retain a larger value pool than atorvastatin on a per-prescription basis. Its trajectory depends on:

Continued statin intensification.
Use in statin-intolerant patients.
Adoption of combination tablets.
Generic penetration.
Competition from bempedoic acid and injectable LDL-lowering medicines.
Reimbursement rules governing step therapy.

The financial profile is therefore defensive rather than high-growth. Neither molecule offers a credible near-term path to originator-like monopoly economics.

Key Takeaways

Atorvastatin calcium is a fully genericized, high-volume statin market.
Lipitor's core U.S. patent protection expired in 2011.
Ezetimibe lost core U.S. exclusivity later, with generic competition expanding from 2017 onward.
Ezetimibe retains greater commercial value because it is used as an add-on and in fixed-dose combinations.
Neither product has meaningful biosimilar risk because both are small molecules subject to ANDA competition.
Combination products, regional brands, manufacturing efficiency, and supply reliability are the main remaining commercial opportunities.
Organon retains branded exposure through Zetia and related products, but generic erosion limits pricing power.
Atorvastatin revenue is volume-driven; ezetimibe revenue has a stronger combination and branded-market component.
Current patent risk is concentrated in formulations, combinations, manufacturing processes, and jurisdiction-specific claims.
The long-term market outlook is stable in volume and declining in unit price.

FAQs

Does atorvastatin calcium still have patent protection?

The core U.S. atorvastatin patents expired in 2011, and multiple generic manufacturers supply the market. Remaining patents, where applicable, generally concern specific formulations, combinations, or manufacturing methods rather than the basic molecule.

Is ezetimibe still protected by the Orange Book?

Ezetimibe products may retain listed secondary patents, but the core U.S. exclusivity period has ended and generic ezetimibe is widely available. Orange Book listings should be reviewed product by product because patent coverage differs among Zetia, combination products, and authorized generics.

Is atorvastatin-ezetimibe a biosimilar product?

No. Atorvastatin-ezetimibe is a small-molecule fixed-dose combination. Competitors seek approval through ANDAs or equivalent national generic pathways, not through the biosimilar framework.

Which drug has stronger commercial prospects, atorvastatin or ezetimibe?

Ezetimibe has stronger residual commercial prospects because it has a differentiated mechanism and is used with statins. Atorvastatin has greater prescription volume but substantially lower pricing power.

Can a generic company obtain premium pricing for atorvastatin-ezetimibe?

Premium pricing is difficult in the United States because of generic substitution and payer control. Better economics may be available through differentiated strengths, regional approvals, supply contracts, and markets where fixed-dose combination use is established.

References

U.S. Food and Drug Administration. (2024). Lipitor (atorvastatin calcium) prescribing information. https://www.accessdata.fda.gov
U.S. Food and Drug Administration. (2024). Zetia (ezetimibe) prescribing information. https://www.accessdata.fda.gov
Pfizer Inc. (2011). Annual report 2010. https://www.pfizer.com/investors/financial-reports
Merck & Co., Inc. (2017). Annual report 2016. https://www.merck.com/investor-relations/financial-information/
Organon & Co. (2024). Annual report 2023. https://www.organon.com/investors/financial-information/
U.S. Patent and Trademark Office. (1987). U.S. Patent No. 4,681,893: Trans-6-[2-(3- or 4-substituted-1H-indol-2-yl)ethyl]-2,2-dimethyl-1,3-dioxane-4-pentanoic acid. https://patents.google.com
U.S. Patent and Trademark Office. (1998). U.S. Patent No. 5,767,115: Azetidinone compounds for the treatment of hypercholesterolemia. https://patents.google.com
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

US Patents:	0
Tradenames:	2
Applicants:	2
NDAs:	2
Clinical Trials:	4
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ATORVASTATIN CALCIUM; EZETIMIBE
DailyMed Link:	ATORVASTATIN CALCIUM; EZETIMIBE at DailyMed

ATORVASTATIN CALCIUM; EZETIMIBE - Generic Drug Details

What are the generic sources for atorvastatin calcium; ezetimibe and what is the scope of freedom to operate?

Summary for ATORVASTATIN CALCIUM; EZETIMIBE

Recent Clinical Trials for ATORVASTATIN CALCIUM; EZETIMIBE

Anatomical Therapeutic Chemical (ATC) Classes for ATORVASTATIN CALCIUM; EZETIMIBE

US Patents and Regulatory Information for ATORVASTATIN CALCIUM; EZETIMIBE

Atorvastatin Calcium and Ezetimibe Market Dynamics, Patent Expiry, and Financial Trajectory